TiGenix confirms Takeda’s intention to acquire company

AZ licences NASH treatment from Ionis for $30m
Credit: Shutterstock.com/ ASDF_MEDIA

TiGenix has confirmed speculation that Takeda intends to launch a voluntary conditional takeover bid of the Belgian biopharma company.

The bid will be subject to Takeda and its affiliates owning at least 85% of the securities of TiGenix with voting rights on a fully diluted basis – as well as European regulatory approvals.

The bid is backed by TiGenix’ board of directors.

CEO Eduardo Bravo said: “We believe the intended takeover bid of Takeda is a positive step for TiGenix’ security holders and reflects the true value of our dedication to patients over the last few years.”